CohBar is developing mitochondria based therapeutics to treat chronic and age related diseases. The mitochondrial genome produces/encodes a number of peptides which are used to regulate metabolism and protect the cell. Exercise increases their production, while certain metabolic conditions such as diabetes and obesity, as well as aging itself, leads to a decline. Based in part on the work of co-founder Pinchas Cohen, CohBar is creating analogues of these mitochondrial-derived peptides (MDPs).

CohBar’s lead candidate, CB4211, is an analogue of MOTS-c, a MDP which can improve obesity and insulin resistance, and exercise capacity. In August 2021, topline Phase 1a/1b study results were released for nonalcoholic steatohepatitis (NASH) and obesity, which showed a reduction in markers for liver damage, as well as lower blood glucose and weight after four weeks.

요약: 1상 통과한듯.

번역까지 하기는 귀찮고 몇몇 단어 뜻풀이 정도는 올려드림.

* analogue: 유사한 것

* topline: 상단에 게재할 만한, 가장 중요한

* steatohepatitis: 지방축적에 의한 간염(hepatitis)의 일종

* liver damage: 간 손상

* glocuse: 포도당